New Non-partisan Group Will Fight to Protect Biopharmaceutical Innovation and Patient Access
The Alliance to Protect Medical Innovation (APMI) will educate the public about medical breakthroughs and fact-check policies that would limit lifesaving cures and treatments
WASHINGTON D.C. – The Alliance to Protect Medical Innovation (APMI) officially launched today, joining the national conversation on medical innovation and patient access. As a nonpartisan 501 (c)(4), APMI will help educate policymakers and the public about medical breakthroughs developed by the biopharmaceutical industry that have saved and prolonged patients’ lives. APMI will also fact-check outside groups promoting dangerous policies that will limit biomedical innovation.
Patients now have access to more life-changing medicines than ever before. New medical breakthroughs are treating – and even curing – once-untreatable conditions and diseases. This type of innovation depends on scientists, doctors, researchers, patients, investors, business leaders and others who are devoted to the discovery and development of new treatments and cures. APMI is committed to preserving the pipeline of breakthrough medicines that reduce costs within the health-care system and help people live longer, healthier and more productive lives.
But this pipeline is under attack. Insurance companies, pharmacy benefit managers and a well-funded network of outside partisan organizations, led by the Arnold Foundation, have been pressuring candidates and policymakers to adopt short-sighted policies that would disrupt the development of the cures and medicines that patients depend on. APMI will serve as a much-needed voice to fact-check these dangerous proposals that would limit investment in biomedical research and stifle the development of innovative cures.
For all press inquiries, please contact us at email@example.com